A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America.
CONCLUSION: Denosumab's efficacy in delaying or preventing SREs, potential to improve PFS, and lack of renal toxicity makes it a cost-effective option for the prevention of SREs in MM compared with zoledronic acid.
PMID: 29480139 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
More News: Economics | Health Management | Myeloma | Reclast | Study | Toxicology | USA Health | Xgeva | Zometa